Targets › GENT
1 program from 1 company in 1 trial: 1 Phase 3; Gastroenterology; next expected readout Jun 2027.
Open in Phaseline: the race on GENT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Spaarne Gasthuis | Gentamicin Bacterial 70S ribosome inhibitor | GENT, CLIND | Phase 3 | Complicated Appendicitis | Jun 2027 |
Complicated Appendicitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.